Annexure-II

Sl. No.	Name of the Company	Year ending	Profit before tax on formulation activity (Rs./lakhs)
1	M/s. Glaxo Labs. (India) Ltd.	June, 1982	579·6
		June, 1983	795·7
		June, 1984	682·20
2	M/s. Merind Ltd.	December, 1982	79·90
		December, 1983	3·69
		December, 1984	167·20
3	M/s. Wyeth Labs. Ltd.	October, 1982	69·76
		October, 1983	44·88
		October, 1984	46·60
4	M/s. Geoffery Manners & Co. Ltd.	October, 1982	N. A.
		October, 1983	159·72
		October, 1984	100·01
5	M/s. Richardson Hindustan Ltd.	June, 1982	198·00
		June, 1984	279·00
		June, 1985	48·00

Production of steriods

860. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) the names of the units licenced to produce harmones, steriods and their intermediates from basic stages i.e. Diosgenin and Solasodine alongwith the names of specific drugs and intermediates licenced to each, capacity permitted and production of each during the last three years, year-wise.

(b) whether it is a fact that indigenous technology for producing steriods was developed about 25 years back by a CSIR laboratory;

(c) if so, the name of the laboratory;

(d) whether it is also a fact that huge capacities were created for the production of steriods and its intermediates and the same are lying idle;

(e) whether it is also a fact that the basic materials i.e. Diosgenin and Solasodine are banned for import but the intermediates being manufactured from these are allowed for import under OGL; and

(f) if so, what were the basis for such recommendations by his Department

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) M/s. Glaxo and M/s. Wyeth are licensed to produce Betamethasone and Prednisolone respectively from basic stage. M/s. Cadila and M/s. T.N. Dadha are licensed to produce Dexamethasone and Betamethasone respectively from

intermediate stages for 2 years. Details of licenced capacity and production to the extent information is available, are given in the Annexure.

(b) and (c) Information is being collected and will be laid on the table of the House.

(d) No, Sir.

(e) Diosgenin and Solasodine are not banned for import under the Export and Import Policy.

(f) Does not arise.

Annexure

Sl. No.	Name of the Bulk drug/ Name of the company	Licens d Capacity	Production (Kgs.)		
			1982-83	1983-84	1984-85
I.	*BETAMETHASONE*				
	(i) Glaxo Labs.	425·00	583·00	613·88	712·64
	(ii) T.N. Dadha	20·00	5·41	..	20·20
II.	*DEXAMETHASONE*				
	(i) Merind	120·00	152·39	128·38	160·75
	(ii) Cadila Labs.	400·00	6·25	9·41	53·31
III.	*PREDENISOLONE*				
	Wyeth Labs.	1719·00	824·00	1,846·00	1,682·00

Anti-Leprosy Drugs

861. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state:

(a) the names of the drugs being marketed for leprosy disease;

(b) how many of these drugs are being imported into the country;

(c) what is the present custom duty imposed on each drug and what is the mark up allowed on the formulations based on each drug according to Drugs Price Control Order, 1979;

(d) whether there are any other drugs for other indications for which lower mark ups, than this, are allowed, if so, what are the names of those drugs; and

(e) what are the reasons for allowing higher mark up for medicines used by leprosy patients?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The major drugs used for treatment of Leprosy are Dapsone, Clofazimine, and Rifampicin.

(b) During the year 1984-85 there were no imports of Clofazimine, Dapsone was partially imported and Rifampicin was completely imported. Commencement of production of Rifampicin was recently reported.

(c) Customs duty on Dapsone is 90 per cent *ad-valorem* whereas Clofazimine and Rifampicin are levied nil rate of custom duty. Dapsone formulations are allowed a mark-up of 40 per cent on the ex-factory cost whereas the formulations based on the other two drugs are allowed a mark-up of upto 100 per cent on the ex-factory cost.